Kyverna Therapeutics Faces Class Action Lawsuit Over Alleged Securities Violations

LOS ANGELES, Dec. 11, 2024 /PRNewswire/ — The Schall Law Firm, a national firm specializing in shareholder rights litigation, has initiated a class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) KYTX for alleged violations of federal securities laws.

Investors who bought the Company’s securities based on documents linked to its initial public offering (“IPO”) on February 8, 2024, should contact the firm before February 7, 2025.

If you experienced financial losses as a shareholder, please click here to participate.

For further assistance, reach out to Brian Schall at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335. You can also visit the firm’s website at www.schallfirm.com or email at bschall@schallfirm.com.

Please note that the class in this lawsuit has not yet been certified. Until certification, you are not represented by an attorney. You may remain an absent class member if you choose not to take action.

The Complaint alleges that the Company misled investors with false statements. Kyverna allegedly withheld adverse data regarding one of its clinical trials, which distorted the information provided in its offering documents. The discussion of risk factors was reportedly inadequate, failing to disclose the risk of concealing clinical data. Consequently, when the true information about Kyverna became public, affected investors faced significant losses.

Join the attempt to recover your losses.

The Schall Law Firm, which represents global investors, focuses on securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in certain jurisdictions as per applicable laws and ethical rules.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/kytx-investors-have-opportunity-to-lead-kyverna-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302328491.html

SOURCE The Schall Law Firm